The Brighterside of News on MSN
Experimental drug can sharply reduce amyloid beta's impact on Alzheimer’s
Early in Alzheimer’s disease, your brain can begin to change long before anyone notices a lost name or missed appointment.
Elevidys’ sales missed Q4 analyst estimates, though Sarepta’s CEO Douglas Ingram is confident of a more stable 2026 for the ...
Jefferies analysts forecast a $1 billion market opportunity for each of Sarepta’s siRNA programs for facioscapulohumeral muscular dystrophy and myotonic dystrophy type 1.
Dr. Torsten Matthias, Geschäftsführer der MODAG GmbH: ...
French marine skincare and spa brand Phytomer has released a serum called Oligoperformance that features marine exosomes, or ...
Prefoldin 5 stabilises neuronal microtubules and suppresses Tau-mediated neurotoxicity, offering a potential therapeutic target for tauopathies.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback